StockData
Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc. (PACB) company profile

PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$1.84−0.12 (-6.12%)

Close on Nov 16, 2026Market cap $571.93MP/E –Yield 0.00%

About Pacific Biosciences of California

Laboratory Analytical Instruments, SIC 3826

PacBio designs, manufactures, and sells genomic sequencing systems, microchips, and reagents built on its proprietary Single-Molecule Real-Time sequencing technology. Its products, which include Revio, Vega, and Sequel instruments alongside SMRT Cells and specialized assay kits, enable high-accuracy long-read sequencing of DNA and RNA. Researchers deploy these tools across rare disease research, human germline analysis, oncology, infectious disease surveillance, and plant and animal biology. The company supplies academic and governmental institutions, commercial laboratories, clinical research facilities, hospitals, agricultural enterprises, and biopharmaceutical organizations.

The company operates a primary manufacturing and service facility in Menlo Park, California, supported by domestic and international contract manufacturers. It markets and distributes its sequencing platforms worldwide through a direct sales organization alongside distribution partners across Europe, Australia, parts of Asia, the Middle East, Africa, Central America, and South America.

Summary of the business section of Pacific Biosciences of California's latest annual report, written by StockData.

Company profile

Company

Legal name
Pacific Biosciences of California, Inc.
Founded
2004
Headquarters
Menlo Park, CA
Address
1305 O'Brien Drive 94025
Phone
(650) 521-8000
Employees
485, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
PACB
Exchange
Nasdaq
IPO date
Oct 27, 2010
Shares outstanding
311M, Jul 31, 2026
Public float
$369.90M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1299130
CUSIP
69404D108
ISIN
US69404D1081
FIGI
BBG000QKXH20
Share class FIGI
BBG001SS9G64
LEI
529900F1BWRE1M0KZN89
EIN
16-1590339

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William MeyerSee Remarks44,000
James R. Gibson IISee Remarks1,083,848
Oene Mark VanSee Remarks2,705,853
Michele FarmerSee Remarks305,948
Christian O. HenrySee Remarks3,581,813
Randall S. LivingstonDirector22,821
William W. EricsonDirector4,890,013
Kathy OrdonezDirector403,037
Christopher GibsonDirector111,386
Christopher M. SmithDirector54,099
Marshall MohrDirector132,821
John F. MilliganDirector132,821
Hannah ValantineDirector22,821
Lucy ShapiroDirector22,821

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.31M$5.53M$2.93M$7$125
FY2024$9.18M-$5.98M$3.60M$7$93
FY2023$8.05M$10.05M$3.22M$38$94
FY2022$6.62M-$13.14M$4.47M$32$90
FY2021$2.87M-$6.45M$11.10M$79$100
FY2020$12.48M$51.60M$1.86M$505$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payTotalvs. prior year
Christian O. Henry
President and Chief Executive Officer
$748.25K$1.15M$1.70M$714.31K$4.31M-53%
Jim R. Gibson
Chief Financial Officer
$376.92K$1.18M$1.74M$198.07K$3.49M–
Mark Van Oene
Chief Operating Officer
$620.13K$561.47K$827.45K$357.07K$2.37M-51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 485 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 2, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 20, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 18, 2018Merger voteDefinitive merger proxy statement
Jun 21, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 6, 2010ListingRegistration of securities on an exchange (Form 8-A)
Jul 28, 2004Name changeName changed from NANOFLUIDICS INC to PACIFIC BIOSCIENCES OF CALIFORNIA INC

See a number that looks wrong?